NewsDialy

California Supreme Court rules Gilead Sciences has no legal duty to fast-track a safer HIV drug

8/4/2026

Pharmaceutical companies do not owe patients a legal duty to speed up development of a safer drug simply because a less safe version is already on the market.

That concept, called a "duty to innovate," was at the center of a case brought by more than 24,000 HIV patients against Gilead Sciences.

California's Supreme Court rejected it in a 6-to-1 ruling, overturning a state appeals court decision and closing off what had been the theory's strongest legal footing.

What the patients argued The plaintiffs said Gilead Sciences had a safer HIV treatment in development and chose to delay it while continuing to sell an older drug.